Prognosis of metastatic castration-resistant prostate cancer in the era of the second-generation androgen receptor-targeted agents: A retrospective multicenter study

Int J Urol. 2021 Jan;28(1):125-127. doi: 10.1111/iju.14392. Epub 2020 Oct 8.

Authors

Hiromichi Iwamura¹, Shingo Hatakeyama¹, Shintaro Narita², Yoichi Arai³, Tomonori Habuchi², Chikara Ohyama¹

Affiliations

¹ Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
² Department of Urology, Akita University School of Medicine, Akita, Japan.
³ Department of Urology, Miyagi Cancer Center, Natori, Miyagi, Japan.

PMID: 33034051
DOI: 10.1111/iju.14392

No abstract available

Publication types

Multicenter Study

MeSH terms

Androgen Antagonists / therapeutic use
Humans
Male
Phenylthiohydantoin / therapeutic use
Prognosis
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Receptors, Androgen*
Retrospective Studies

Substances

Androgen Antagonists
Receptors, Androgen
Phenylthiohydantoin